AstraZeneca wins two approval recommendations from EU agency
Oct 19 (Reuters) - The European medicines watchdog has recommended approving AstraZeneca Plc's AZN.L treatments for a form of heart failure and a lung disorder, the British drugmaker said on Monday.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Forxiga for treating a form of heart failure and Trixeo Aerosphere for a form of lung disorder known as "smoker's lung".
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Aditya Soni)
((Aakash.B@thomsonreuters.com; Twitter: @JagadeeshAakash;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.